28 related articles for article (PubMed ID: 15901984)
1. Infection risk in patients with autoimmune cytopenias and immune dysregulation treated with mycophenolate mofetil and sirolimus.
Comella M; Palmisani E; Mariani M; Dell'Orso G; Licciardello M; Giarratana MC; Arcuri L; Pestarino S; Grossi A; Lanciotti M; Brucci G; Guardo D; Russo G; Dufour C; Fioredda F; Castagnola E; Miano M
Front Immunol; 2024; 15():1415389. PubMed ID: 38873600
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
[TBL] [Abstract][Full Text] [Related]
3. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
[TBL] [Abstract][Full Text] [Related]
4. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
5. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
[TBL] [Abstract][Full Text] [Related]
6. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs.
Renders L; Steinbach R; Valerius T; Schöcklmann HO; Kunzendorf U
Kidney Blood Press Res; 2004; 27(3):181-5. PubMed ID: 15256815
[TBL] [Abstract][Full Text] [Related]
7. [The first experience with sirolimus (Rapamune) after kidney transplantation in Lithuania].
Asakiene E; Rainiene T; Dainys B
Medicina (Kaunas); 2005; 41 Suppl 1():93-100. PubMed ID: 15901984
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus (Rapamune) in renal transplantation.
Johnson RW
Curr Opin Nephrol Hypertens; 2002 Nov; 11(6):603-7. PubMed ID: 12394605
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients.
Maramattom BV; Wijdicks EF
Neurology; 2004 Nov; 63(10):1958-9. PubMed ID: 15557524
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus: a comprehensive review.
Kahan BD
Expert Opin Pharmacother; 2001 Nov; 2(11):1903-17. PubMed ID: 11825325
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus: a new promising immunosuppressive drug. Towards a rationale for its use in renal transplantation.
Morelon E; Mamzer-Bruneel MF; Peraldi MN; Kreis H
Nephrol Dial Transplant; 2001 Jan; 16(1):18-20. PubMed ID: 11208987
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
